Divi's Laboratories (NSE:DIVISLAB) Notes Receivable: ₹0 Mil (As of Mar. 2026)


NSE:DIVISLAB Divi's Laboratories Ltd NSE:DIVISLAB
94 GF Score
Price ₹6,713.50
GF Value ₹6,732.51
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Divi's Laboratories Notes Receivable?

Divi's Laboratories NSE:DIVISLAB -0.59% 94 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 94/100 and a GF Value™ of ₹6,732.51 (Fairly Valued). The stock has 5 warning signs investors should review.

Divi's Laboratories's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Divi's Laboratories Notes Receivable Related Terms

Divi's Laboratories Notes Receivable Historical Data

* Premium members only.

The historical data trend for Divi's Laboratories's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Divi's Laboratories Notes Receivable Chart

Divi's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Divi's Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:DIVISLAB
94GF Score
Divi's Laboratories Ltd NSE:DIVISLAB
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Divi's Laboratories Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Divi's Laboratories (NSE:DIVISLAB) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Divi's Laboratories and its competitors.
Is Divi's Laboratories' Notes Receivable too high?
Divi's Laboratories' current Notes Receivable is ₹0 Mil. Overall, Divi's Laboratories has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' Notes Receivable compare to ZTS?
Divi's Laboratories' Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Divi's Laboratories and its competitors. Divi's Laboratories's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,732.51, compared to a current price of ₹6,713.50 — trading 0.3% below its estimated fair value. The current Notes Receivable is ₹0 Mil. Divi's Laboratories' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Divi's Laboratories stock appears to be undervalued. The current stock price of ₹6,713.50 is trading 0.3% below its estimated GF Value™ of ₹6,732.51. GuruFocus considers Divi's Laboratories to be Fairly Valued.

Key valuation signals for NSE:DIVISLAB:

  • Notes Receivable: ₹0 Mil
  • GF Value™: ₹6,732.51 vs. price of ₹6,713.50 (0.3% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Divi's Laboratories Business Description

Other Exchanges 532488:India
Address Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
94GF Score

Get the complete analysis for NSE:DIVISLAB

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,713.50
Price
₹6,732.51
GF Value